Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial

Andel, M.M. van; Indrakusuma, R.; Jalalzadeh, H.; Balm, R.; Timmermans, J.; Scholte, A.J.; Berg, M.P. van den; Zwinderman, A.H.; Mulder, B.J.M.; Waard, V. de; Groenink, M.

doi:doi:10.1093/eurheartj/ehaa377

Aims The COMPARE trial showed a small but significant beneficial effect of 3-year losartan treatment on aortic root dilatation rate in adults with Marfan syndrome (MFS). However, no significant effect was found on clinical endpoints, possibly due to a short follow-up period. The aim of the current study was therefore to investigate the long-term clinical outcomes after losartan treatment.Methods and In the original COMPARE study (inclusion 2008-2009), adult patients with MFS (n=233) were randomly allocated results to either the angiotensin-II receptor blacker losartan on top of regular treatment (beta-blockers in 71% of the patients) or no additional medication. After the COMPARE trial period of 3 years, study subjects chose to continue their losartan medication or not. In a median follow-up period of 8 years, 75 patients continued losartan medication, whereas 78 patients, originally allocated to the control group, never used losartan after inclusion. No differences existed between...Show moreAims The COMPARE trial showed a small but significant beneficial effect of 3-year losartan treatment on aortic root dilatation rate in adults with Marfan syndrome (MFS). However, no significant effect was found on clinical endpoints, possibly due to a short follow-up period. The aim of the current study was therefore to investigate the long-term clinical outcomes after losartan treatment.Methods and In the original COMPARE study (inclusion 2008-2009), adult patients with MFS (n=233) were randomly allocated results to either the angiotensin-II receptor blacker losartan on top of regular treatment (beta-blockers in 71% of the patients) or no additional medication. After the COMPARE trial period of 3 years, study subjects chose to continue their losartan medication or not. In a median follow-up period of 8 years, 75 patients continued losartan medication, whereas 78 patients, originally allocated to the control group, never used losartan after inclusion. No differences existed between baseline characteristics of the two groups except for age at inclusion [losartan 34 (interquartile range, IQR 26-43) years, control 41 (IQR 30-52) years; P=0.031], and beta-blacker use (losartan 81%, control 64%; P=0.022). A pathological FBN1 mutation was present in 76% of patients and 58% of the patients were male. Clinical endpoints, defined as all-cause mortality, aortic dissection/rupture, elective aortic root replacement, reoperation, and vascular graft implantation beyond the aortic root, were compared between the two groups. A per-patient composite endpoint was also analysed. Five deaths, 14 aortic dissections, 23 aortic root replacements, 3 reoperations, and 3 vascular graft implantations beyond the aortic root occurred during follow-up. Except for aortic root replacement, all endpoints occurred in patients with an operated aortic root. Patients who used losartan during the entire follow-up period showed a reduced number of events compared to the control group (death: 0 vs. 5, P=0.014; aortic dissection: 3 vs. 11, P=0.013; elective aortic root replacement: 10 vs. 13, P=0.264; reoperation: 1 vs. 2, P=0.463; vascular graft implantations beyond the aortic root 0 vs. 3, P=0.071; and composite endpoint: 14 vs. 26, P=0.019). These results remained similar when corrected for age and beta-blocker use in a multivariate analysis.Conclusion: These results suggest a clinical benefit of combined losartan and beta-blocker treatment in patients with MFS.Show less

Leiden University Scholarly Publications

View statistics

Documents

In Collections

Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial